High Expression of High-Mobility Group Box 1 in Menstrual Blood: Implications for Endometriosis

Keiko Shimizu, Yasuhiko Kamada, Ai Sakamoto, Miwa Matsuda, Mikiya Nakatsuka, Yuji Hiramatsu

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Endometriosis is a benign gynecologic disease characterized by the presence of ectopic endometrium and associated with inflammation and immune abnormalities. However, the molecular basis for endometriosis is not well understood. To address this issue, the present study examined the expression of high-mobility group box (HMGB) 1 in menstrual blood to investigate its role in the ectopic growth of human endometriotic stromal cells (ESCs). A total of 139 patients were enrolled in this study; 84 had endometriosis and 55 were nonendometriotic gynecological patients (control). The HMGB1 levels in various fluids were measured by enzyme-linked immunosorbent assay. Expression of receptor for advanced glycation end products (RAGE) in eutopic and ectopic endometrium was assessed by immunohistochemistry, and RAGE and vascular endothelial growth factor (VEGF) messenger RNA expression in HMGB1- and lipopolysaccharide (LPS)-treated ESCs was evaluated by real-time polymerase chain reaction. The HMGB1 concentration was higher in menstrual blood than in serum or peritoneal fluid (P <.001 for both). RAGE was expressed in both normal and ectopic endometrium. Administration of 1000 ng/mL HMGB1 or coadministration of 100 ng/mL HMGB1 and 100 ng/mL LPS induced VEGF production in ESCs relative to the control (P <.05). These results suggest that menstrual fluid has naturally high levels of HMGB1 and may promote endometriosis following retrograde menstruation when complexed with other factors such as LPS by inducing inflammation and angiogenesis.

Original languageEnglish
Pages (from-to)1532-1537
Number of pages6
JournalReproductive Sciences
Volume24
Issue number11
DOIs
Publication statusPublished - Nov 1 2017

Fingerprint

HMGB1 Protein
Endometriosis
Stromal Cells
Endometrium
Lipopolysaccharides
Vascular Endothelial Growth Factor A
Menstruation Disturbances
Female Genital Diseases
Inflammation
Ascitic Fluid
Real-Time Polymerase Chain Reaction
Enzyme-Linked Immunosorbent Assay
Immunohistochemistry
Messenger RNA
Growth
Serum
Advanced Glycosylation End Product-Specific Receptor

Keywords

  • endometriosis
  • high-mobility group box 1
  • lipopolysaccharide
  • receptor for advanced glycation end products
  • vascular endothelial growth factor

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

High Expression of High-Mobility Group Box 1 in Menstrual Blood : Implications for Endometriosis. / Shimizu, Keiko; Kamada, Yasuhiko; Sakamoto, Ai; Matsuda, Miwa; Nakatsuka, Mikiya; Hiramatsu, Yuji.

In: Reproductive Sciences, Vol. 24, No. 11, 01.11.2017, p. 1532-1537.

Research output: Contribution to journalArticle

Shimizu, Keiko ; Kamada, Yasuhiko ; Sakamoto, Ai ; Matsuda, Miwa ; Nakatsuka, Mikiya ; Hiramatsu, Yuji. / High Expression of High-Mobility Group Box 1 in Menstrual Blood : Implications for Endometriosis. In: Reproductive Sciences. 2017 ; Vol. 24, No. 11. pp. 1532-1537.
@article{778d815fde2a49baae7b2f18b21468fb,
title = "High Expression of High-Mobility Group Box 1 in Menstrual Blood: Implications for Endometriosis",
abstract = "Endometriosis is a benign gynecologic disease characterized by the presence of ectopic endometrium and associated with inflammation and immune abnormalities. However, the molecular basis for endometriosis is not well understood. To address this issue, the present study examined the expression of high-mobility group box (HMGB) 1 in menstrual blood to investigate its role in the ectopic growth of human endometriotic stromal cells (ESCs). A total of 139 patients were enrolled in this study; 84 had endometriosis and 55 were nonendometriotic gynecological patients (control). The HMGB1 levels in various fluids were measured by enzyme-linked immunosorbent assay. Expression of receptor for advanced glycation end products (RAGE) in eutopic and ectopic endometrium was assessed by immunohistochemistry, and RAGE and vascular endothelial growth factor (VEGF) messenger RNA expression in HMGB1- and lipopolysaccharide (LPS)-treated ESCs was evaluated by real-time polymerase chain reaction. The HMGB1 concentration was higher in menstrual blood than in serum or peritoneal fluid (P <.001 for both). RAGE was expressed in both normal and ectopic endometrium. Administration of 1000 ng/mL HMGB1 or coadministration of 100 ng/mL HMGB1 and 100 ng/mL LPS induced VEGF production in ESCs relative to the control (P <.05). These results suggest that menstrual fluid has naturally high levels of HMGB1 and may promote endometriosis following retrograde menstruation when complexed with other factors such as LPS by inducing inflammation and angiogenesis.",
keywords = "endometriosis, high-mobility group box 1, lipopolysaccharide, receptor for advanced glycation end products, vascular endothelial growth factor",
author = "Keiko Shimizu and Yasuhiko Kamada and Ai Sakamoto and Miwa Matsuda and Mikiya Nakatsuka and Yuji Hiramatsu",
year = "2017",
month = "11",
day = "1",
doi = "10.1177/1933719117692042",
language = "English",
volume = "24",
pages = "1532--1537",
journal = "Reproductive Sciences",
issn = "1933-7191",
publisher = "SAGE Publications Inc.",
number = "11",

}

TY - JOUR

T1 - High Expression of High-Mobility Group Box 1 in Menstrual Blood

T2 - Implications for Endometriosis

AU - Shimizu, Keiko

AU - Kamada, Yasuhiko

AU - Sakamoto, Ai

AU - Matsuda, Miwa

AU - Nakatsuka, Mikiya

AU - Hiramatsu, Yuji

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Endometriosis is a benign gynecologic disease characterized by the presence of ectopic endometrium and associated with inflammation and immune abnormalities. However, the molecular basis for endometriosis is not well understood. To address this issue, the present study examined the expression of high-mobility group box (HMGB) 1 in menstrual blood to investigate its role in the ectopic growth of human endometriotic stromal cells (ESCs). A total of 139 patients were enrolled in this study; 84 had endometriosis and 55 were nonendometriotic gynecological patients (control). The HMGB1 levels in various fluids were measured by enzyme-linked immunosorbent assay. Expression of receptor for advanced glycation end products (RAGE) in eutopic and ectopic endometrium was assessed by immunohistochemistry, and RAGE and vascular endothelial growth factor (VEGF) messenger RNA expression in HMGB1- and lipopolysaccharide (LPS)-treated ESCs was evaluated by real-time polymerase chain reaction. The HMGB1 concentration was higher in menstrual blood than in serum or peritoneal fluid (P <.001 for both). RAGE was expressed in both normal and ectopic endometrium. Administration of 1000 ng/mL HMGB1 or coadministration of 100 ng/mL HMGB1 and 100 ng/mL LPS induced VEGF production in ESCs relative to the control (P <.05). These results suggest that menstrual fluid has naturally high levels of HMGB1 and may promote endometriosis following retrograde menstruation when complexed with other factors such as LPS by inducing inflammation and angiogenesis.

AB - Endometriosis is a benign gynecologic disease characterized by the presence of ectopic endometrium and associated with inflammation and immune abnormalities. However, the molecular basis for endometriosis is not well understood. To address this issue, the present study examined the expression of high-mobility group box (HMGB) 1 in menstrual blood to investigate its role in the ectopic growth of human endometriotic stromal cells (ESCs). A total of 139 patients were enrolled in this study; 84 had endometriosis and 55 were nonendometriotic gynecological patients (control). The HMGB1 levels in various fluids were measured by enzyme-linked immunosorbent assay. Expression of receptor for advanced glycation end products (RAGE) in eutopic and ectopic endometrium was assessed by immunohistochemistry, and RAGE and vascular endothelial growth factor (VEGF) messenger RNA expression in HMGB1- and lipopolysaccharide (LPS)-treated ESCs was evaluated by real-time polymerase chain reaction. The HMGB1 concentration was higher in menstrual blood than in serum or peritoneal fluid (P <.001 for both). RAGE was expressed in both normal and ectopic endometrium. Administration of 1000 ng/mL HMGB1 or coadministration of 100 ng/mL HMGB1 and 100 ng/mL LPS induced VEGF production in ESCs relative to the control (P <.05). These results suggest that menstrual fluid has naturally high levels of HMGB1 and may promote endometriosis following retrograde menstruation when complexed with other factors such as LPS by inducing inflammation and angiogenesis.

KW - endometriosis

KW - high-mobility group box 1

KW - lipopolysaccharide

KW - receptor for advanced glycation end products

KW - vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=85031302628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031302628&partnerID=8YFLogxK

U2 - 10.1177/1933719117692042

DO - 10.1177/1933719117692042

M3 - Article

C2 - 29017437

AN - SCOPUS:85031302628

VL - 24

SP - 1532

EP - 1537

JO - Reproductive Sciences

JF - Reproductive Sciences

SN - 1933-7191

IS - 11

ER -